Steven Grant, M.D.
Affiliations: | Virginia Commonwealth University, Richmond, VA, United States |
Area:
Pharmacology, BiochemistryWebsite:
https://medschool.vcu.edu/expertise/detail.html?ID=845Google:
"Steven Grant"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Edwin C. Cadman | post-doc | 1978-1980 | Yale School of Medicine (Cell Biology Tree) |
Children
Sign in to add trainee| Roy H. Decker | grad student | 2001 | VCU |
| Shujie Wang | grad student | 2002 | VCU |
| Wesam B. Ahmed | grad student | 2003 | VCU |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Elshazly AM, Hosseini N, Shen S, et al. (2025) Proteasome Inhibition Enhances Lysosome-mediated Targeted Protein Degradation. Biorxiv : the Preprint Server For Biology |
| Hu X, Li L, Nkwocha J, et al. (2025) Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia. Signal Transduction and Targeted Therapy. 10: 50 |
| Bishop RT, Li T, Sudalagunta P, et al. (2024) Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed / refractory multiple myeloma. Haematologica |
| Li L, Hu X, Nkwocha J, et al. (2024) Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivo. British Journal of Haematology |
| Li L, Hu X, Nkwocha J, et al. (2023) Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells. Cellular Oncology (Dordrecht) |
| Bouligny IM, Maher KR, Grant S. (2023) Augmenting Venetoclax Activity Through Signal Transduction in AML. Journal of Cellular Signaling. 4: 1-12 |
| Hu X, Li L, Nkwocha J, et al. (2023) Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells. Hematology Reports. 15: 91-100 |
| Satta T, Li L, Chalasani SL, et al. (2023) Dual mTORC1/2 inhibition synergistically enhances AML cell death in combination with the BCL2 antagonist venetoclax. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Leng Y, Hu X, Li L, et al. (2022) MECHANISMS UNDERLYING SYNERGISM BETWEEN CIRCULARIZED TRAIL (CPT) AND BORTEZOMIB IN BORTEZOMIB-SENSITIVE OR -RESISTANT MYELOMA CELLS. Hematological Oncology |
| Zhou L, Pei X, Zhang Y, et al. (2021) Chk1 inhibition potently blocks STAT3 tyrosine705 phosphorylation, DNA binding activity, and activation of downstream targets in human multiple myeloma cells. Molecular Cancer Research : McR |